We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+33.77%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$15.6B
AUM Growth
+$3.41B
Cap. Flow
-$91.9M
Cap. Flow %
-0.59%
Top 10 Hldgs %
85.51%
Holding
100
New
7
Increased
16
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$48.4M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$32.3M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$30.8M
4
BOLD
Audentes Therapeutics, Inc
BOLD
+$23.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$11.1M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$115M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$46.5M
3
ARRY
Array Biopharma Inc
ARRY
+$25M
4
SLDB icon
Solid Biosciences
SLDB
+$15.8M
5
NVAX icon
Novavax
NVAX
+$8.68M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$3.74B 23.93%
51,049,760
+3,700
+0% +$263K
INCY icon
2
Incyte
INCY
$25.5B
$2.95B 18.87%
34,271,827
+20,220
+0.1% +$1.65M
ONC
3
BeOne Medicines Ltd
ONC
$33.8B
$1.58B 10.11%
11,959,824
– –
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$1.16B 7.41%
8,558,068
+2,174
+0% +$270K
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.43B
$1.07B 6.83%
39,713,842
– –
AMRN
6
Amarin Corp
AMRN
$299M
$897M 5.74%
2,160,523
+30,882
+1% +$11.1M
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$714M 4.57%
10,198,943
-1,545,067
-13% -$115M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12B
$674M 4.32%
7,589,294
– –
ASND icon
9
Ascendis Pharma A/S
ASND
$16.7B
$399M 2.55%
3,390,270
+552,918
+19% +$48.4M
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$184M 1.18%
2,513,462
– –
MDGL icon
11
Madrigal Pharmaceuticals
MDGL
$12.5B
$146M 0.94%
1,169,278
– –
ARGX icon
12
argenx
ARGX
$55.1B
$127M 0.81%
1,019,557
– –
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.43B
$123M 0.79%
15,118,081
+15,000
+0.1% +$128K
HRTX icon
14
Heron Therapeutics
HRTX
$91.6M
$123M 0.79%
5,018,104
– –
CMTA
15
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$97.2M 0.62%
3,724,445
– –
NBIX icon
16
Neurocrine Biosciences
NBIX
$18.2B
$96.8M 0.62%
1,098,670
+368,315
+50% +$30.8M
ARRY
17
DELISTED
Array Biopharma Inc
ARRY
$93.7M 0.6%
3,842,289
-1,199,407
-24% -$25M
NVTA
18
DELISTED
Invitae Corporation
NVTA
$91.4M 0.59%
3,902,421
– –
ONCE
19
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$85.6M 0.55%
751,927
-632,203
-46% -$46.5M
CBAY
20
DELISTED
Cymabay Therapeutics
CBAY
$75.8M 0.49%
5,707,411
+789,711
+16% +$8.4M
RYTM icon
21
Rhythm Pharmaceuticals
RYTM
$7.3B
$74.2M 0.48%
2,708,200
– –
GWPH
22
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$72.2M 0.46%
428,345
– –
TCDA
23
DELISTED
Tricida, Inc. Common Stock
TCDA
$69.6M 0.45%
1,803,238
+203,238
+13% +$4.73M
CERS icon
24
Cerus
CERS
$577M
$67M 0.43%
10,749,937
– –
BOLD
25
DELISTED
Audentes Therapeutics, Inc
BOLD
$66.9M 0.43%
1,715,183
+804,720
+88% +$23.1M
1
2 3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2019 Portfolio in Review

As of Q1 2019, Baker Bros. Advisors held 100 positions worth $15.6B, up 28% from $12.2B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q1 2019 filing shows 7 new, 16 increased, 6 reduced and 4 closed positions. Its largest new stake was Axsome Therapeutics: 1,200,000 shares worth $17.1M. The largest sale was Genomic Health, Inc., an estimated $115M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q1 2019 buy was Axsome Therapeutics: 1,200,000 shares worth $17.1M.
  • Baker Bros. Advisors added most to Ascendis Pharma A/S in Q1 2019, an estimated $48.4M increase.
  • Baker Bros. Advisors's biggest Q1 2019 reduction was Genomic Health, Inc., cutting an estimated $115M.
  • Baker Bros. Advisors fully exited Solid Biosciences in Q1 2019, selling an estimated $15.8M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $15.6B portfolio in Q1 2019.
  • Baker Bros. Advisors opened 7 new positions and closed 4 in Q1 2019.
  • Baker Bros. Advisors's portfolio value rose 28% quarter-over-quarter to $15.6B.

Based on Baker Bros. Advisors's 13F filing for Q1 2019, filed 15 May 2019.